A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
NCT07459634
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Extensive-stage Small-cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Jazz Pharmaceuticals
- Last updated on ClinicalTrials.gov
- September 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Valkyrie Clinical Trials, Inc. · Los Angeles, CA
Florida · 1
- Cancer Specialists of North Florida · Jacksonville, FL
Georgia · 1
- Emory University · Atlanta, GA
Kentucky · 1
- Baptist Health · Lexington, KY
South Carolina · 1
- Carolina Blood and Cancer Care · Rock Hill, SC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.